The approval offers a new therapeutic option to decrease the risk of first myocardial infarction and stroke among patients with coronary artery disease at high risk for such events.
The approval comes after results from 2 phase 3 trials showed that the medication significantly reduced the amount of heavy bleeding compared with placebo.
The approval comes after results from 2 phase 3 trials showed that the medication significantly reduced the amount of heavy bleeding compared with placebo.
The approval comes after results from 2 phase 3 trials showed that the medication significantly reduced the amount of heavy bleeding compared with placebo.
The FDA has granted a landmark approval to an intravenous injection for the imaging of tau pathology among patients with cognitive impairment being evaluated for Alzheimer disease.
The FDA has granted a landmark approval to an intravenous injection for the imaging of tau pathology among patients with cognitive impairment being evaluated for Alzheimer disease.
The FDA has granted a landmark approval to an intravenous injection for the imaging of tau pathology among patients with cognitive impairment being evaluated for Alzheimer disease.
